• AA
  • Share

Endocrine Society Issues Pediatric Obesity Clinical Practice Guideline

On February 1, the Endocrine Society issued a Clinical Practice Guideline advising healthcare providers on how to prevent and treat childhood obesity with lifestyle changes.

The guideline, titled “Pediatric Obesity — Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline,” was published online and will appear in the March 2017 print issue of The Journal of Clinical Endocrinology & Metabolism (JCEM). In addition to prevention and treatment, the guideline provides recommendations on how to evaluate affected children for medical or psychological complications, when to evaluate children for rare genetic causes of obesity, and when to consider medications or surgery for the most severely affected older adolescents.

Pediatric obesity is a pervasive international problem. Seventeen percent of American children and teenagers between the ages of 2 and 19 were affected by obesity in 2011-2014, according to the U.S. Centers for Disease Control and Prevention. Obesity in this age group was associated with an estimated $14.1 billion in additional prescription drugs, emergency room and outpatient medical visit costs each year, according to the Society’s Endocrine Facts & Figures Report.

Children and teenagers are diagnosed as being overweight when an individual’s body-mass index (BMI) is between the 85th and 95th percentile for their age and sex. Obesity occurs when a child or teen’s BMI is greater than or equal to the 95th percentile for their age and sex. A child or teen is diagnosed with extreme obesity when the BMI is greater than or equal to 120% of the 95th percentile.

“Intensive, family-centered lifestyle modifications to encourage healthy diet and activity remain the central approach to preventing and treating obesity in children and teenagers,” says Dennis M. Styne, MD, of the University of California Davis Medical Center in Sacramento. Styne chaired the task force that developed the guideline. “Since the Society last issued a pediatric obesity guideline in 2008, physicians have access to new information on genetic causes of obesity, psychological complications associated with obesity, surgical techniques and medications that are now available for the most severely affected older teenagers. The guideline offers information on incorporating these developments into patient care.”

“Intensive, family-centered lifestyle modifications to encourage healthy diet and activity remain the central approach to preventing and treating obesity in children and teenagers.” – Dennis M. Styne, MD, University of California Davis Medical Center, Sacramento

The guideline authors noted unmet needs for future research include understanding the causes of pediatric obesity and its complications, prevention, and treatment. In addition, research is needed to examine how environmental and economic factors can drive worldwide cultural changes in diet and activity.

Recommendations from the guideline include:

  • Children or teens with a BMI greater than or equal to the 85th percentile should be evaluated for related conditions such as metabolic syndrome and diabetes.
  • Youth being evaluated for obesity do not need to have their fasting insulin values measured because it has no diagnostic value.
  • Children or teens affected by obesity do not need routine laboratory evaluations for endocrine disorders that can cause obesity unless their height or growth rate is less than expected based on age and pubertal stage.
  • About 7% of children with extreme obesity may have rare chromosomal abnormalities or genetic mutations. The guideline suggests specific genetic testing when there is early onset obesity (before five years old), an increased drive to consume food known as extreme hyperphagia, other clinical findings of genetic obesity syndromes, or a family history of extreme obesity.

For more statistics and data on pediatric obesity, visit the Society’s Endocrine Facts & Figures Report.

Other members of the Endocrine Society task force that developed this guideline include: Silva A. Arslanian, MD, University of Pittsburgh, Pittsburgh, Pa.; Ellen L. Connor, MD, University of Wisconsin, Madison; Ismaa Sadaf Farooqi, PhD, University of Cambridge in Cambridge, U.K.; M. Hassan Murad, MD, Mayo Clinic, Rochester, Minn.; Janet H. Silverstein, MD, University of Florida, Gainesville; and Jack A. Yanovski, MD, PhD, National Institutes of Health, Bethesda, Md.

The Society established the Clinical Practice Guideline Program to provide endocrinologists and other clinicians with evidence-based recommendations in the diagnosis, treatment, and management of endocrine-related conditions. Each guideline is created by a task force of topic-related experts in the field. Task forces rely on evidence-based reviews of the literature in the development of guideline recommendations. The Endocrine Society does not solicit or accept corporate support for its guidelines. All Clinical Practice Guidelines are supported entirely by Society funds.

The Clinical Practice Guideline was co-sponsored by the European Society of Endocrinology and the Pediatric Endocrine Society.

The guideline was published online ahead of print.

You may also like

  • Endocrine Society Response to Immigration Order

    President Donald Trump signed an executive order on Friday, January 27, limiting refugees into the U.S., barring the citizens of seven countries – Iraq, Iran, Syria, Somalia, Sudan, Libya, and Yemen – from entering the U.S. on any visa category, and, consequently, also creating new barriers to the global exchange of scientific information. The order…

  • Rare Endocrine Diseases Highlighted in New Awareness Campaign

    A new global campaign has been launched by Alexion Pharmaceuticals, Inc., to raise awareness of bone disorder hypophosphatasia (HPP), metabolic disease lysosomal acid lipase deficiency (LAL-D), and other rare diseases. Uncommon Strength celebrates the extraordinary resilience and inner strength of individuals impacted by these diseases, according to a company statement. Aside from HPP and LAL-D, the…

Find more in